Results
What follows is a brief description of the results, limited to statins (simvastatin, atorvastatin,
pravastatin) other than cerivastatin, and omitting discussion of fibrates.
Rhabdomyolysis
Cohort studies indicate a rate of 3.4 (1.6 to 6.5)/100,000 person years (1 in 29,000 per year) from cohort studies, supported by RCTs and notifications. Mortality with rhabdomyolysis is about 10%, giving a statin-specific death rate of about 1 in 300,000 per year.